Saverna Therapeutics

Executive Summary

Saverna Therapeutics is a Swiss drug discovery company founded in 2017 that leverages a proprietary platform combining artificial intelligence, nuclear magnetic resonance (NMR) spectroscopy, and fragment-based screening to develop orally active small molecules targeting microRNAs (miRNAs). By focusing on non-coding RNA, the company addresses a challenging but high-potential target class for diseases with significant unmet need, including inflammation, autoimmune diseases, cancer, and infection. The platform aims to accelerate and reduce the cost of drug discovery compared to traditional methods. Saverna is privately held and has not disclosed its stage or funding history, suggesting it may still be in early preclinical or discovery phases. The company's innovative approach to modulating miRNA activity orally could offer advantages over existing oligonucleotide-based therapies, potentially enabling broader therapeutic applications and improved patient compliance. However, the field of RNA-targeting small molecules remains nascent, with technical hurdles such as target specificity and bioavailability. Saverna's success will depend on advancing its pipeline, securing partnerships, and demonstrating proof-of-concept in relevant disease models. With no disclosed public milestones, the company's near-term visibility is limited, but its platform technology and experienced Basel-based team position it to contribute to the emerging RNA-targeted small molecule space.

Upcoming Catalysts (preview)

• Q4 2026Selection of first development candidate50% success
• H1 2027Series A financing round60% success
• TBDResearch partnership with pharma/biotech30% success